Previous 10 | Next 10 |
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the dis...
2023-08-21 08:31:22 ET More on GSK, IDEAYA, etc. Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead GSK: A Muted Valuation And Good Dividend Yield GSK Stock: Optimistic After Solid Q2 Growth And Solidifying Guidance GSK Rating Upgraded To...
IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) PR Newswire GSK101 (IDE705) is being developed as a potential first-in-class Pol Theta Helicase Inhibitor in combination with niraparib in GSK-sponsored Phase...
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma PR Newswire Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant the...
2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...
2023-08-11 15:41:02 ET Summary Ideaya Biosciences has made strong progress in the treatment of ocular cancer, with its stock price increasing over 150% since its IPO. The company's lead candidate, Darovasertib, has shown promising results in Phase 2 studies, with high response rat...
2023-08-10 10:54:17 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q2 GAAP EPS of -$0.50 beats by $0.06 . Revenue of $3.54M (-68.8% Y/Y) misses by $0.86M . Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of J...
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 I...
IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors PR Newswire - First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperativ...
IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...